Ocular therapeutix™ announces more than 300 subjects randomized in sol-1

Sol-1 is the first registrational trial for axpaxli™ in wet amd topline clinical data from sol-1 expected in q4 2025 active clinical trial sites enrolling patients directly into second registrational trial, sol-r, while additional sites continue to be activated bedford, mass., dec. 02, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq: ocul, “ocular”, the “company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that more than 300 patients have been randomized in the sol-1 phase 3 trial for axpaxli™ (axitinib intravitreal implant, also known as otx-tki), and the trial is expected to close randomization this week.
SOL Ratings Summary
SOL Quant Ranking